Search for: "APOTEX INC."
Results 1 - 20
of 674
Sort by Relevance
|
Sort by Date
6 May 2024, 9:43 am
C R Bard Inc. v. [read post]
16 Apr 2024, 8:42 am
Apotex Inc., 939 F.3d 1375 (Fed. [read post]
19 Mar 2024, 8:54 am
Apotex, Inc., 480 F.3d 1348 (Fed. [read post]
5 Mar 2024, 10:23 am
Apotex, Inc., 480 F.3d 1348 (Fed. [read post]
21 Feb 2024, 4:00 am
Novopharm Ltd., [1998] 2 S.C.R. 129, 161 DLR (4th) 1, Apotex Inc. v. [read post]
19 Feb 2024, 12:55 pm
Altoona Publix Theatres, Inc. v. [read post]
23 Jan 2024, 3:43 am
Apotex (Fed. [read post]
19 Jan 2024, 4:00 am
In other contexts, there have been concerns that double patenting may increase burdens under the Notice of Compliance regime for pharmaceuticals – see for example, Glaxosmithkline Inc. v Apotex Inc, 2003 FCT 687 at 90: “The existence of additional patents allows the patent-holder to bring additional applications, thereby obtaining multiple injunctive periods. [read post]
11 Dec 2023, 7:43 am
Apotex Inc., 790 F. [read post]
1 Dec 2023, 4:00 am
Les Produits Gilbert Inc., 2008 FCA 35, 67 C.P.R. (4th) 161, para. 13. [3] See Apotex Inc. v. [read post]
31 Oct 2023, 6:31 am
Puriton (Kadesh Inc.) [read post]
31 Oct 2023, 6:31 am
Puriton (Kadesh Inc.) [read post]
31 Oct 2023, 6:31 am
Puriton (Kadesh Inc.) [read post]
27 Oct 2023, 6:17 am
On March 2, 2023, Apotex Corp. issued a recall due to “cracks that have developed” in some of the bottles used to store its Apotex-brand eye drops. [read post]
27 Oct 2023, 6:17 am
On March 2, 2023, Apotex Corp. issued a recall due to “cracks that have developed” in some of the bottles used to store its Apotex-brand eye drops. [read post]
27 Oct 2023, 6:17 am
On March 2, 2023, Apotex Corp. issued a recall due to “cracks that have developed” in some of the bottles used to store its Apotex-brand eye drops. [read post]
17 Aug 2023, 9:00 pm
Tobolowsky —In January 2023, Vanda Pharmaceuticals, Inc. [read post]
31 Jul 2023, 1:47 pm
Apotex Corp., 403 F.3d 1331, 1343–44 (Fed. [read post]
11 Jun 2023, 8:17 pm
Teva Pharmaceuticals USA, Inc. [read post]
12 Apr 2023, 4:00 am
Sandoz Canada Inc., 2023 FC 243 at para 6 quoting from the Regulatory Impact Analysis Statement, (2017) Canada Gazette, Part 1, Vol 151, No 28 at 3317. [3] See Section 7(1)(d), Patented Medicines (NOC) Regulations. [4] See Section 6(3), Patented Medicines (Notice of Compliance) Regulations, subsections (a0 and (b) provide for a counterclaim against asserted claims in a patent or in a certificate of supplementary protection respectively. [5] See Janssen Inc v Apotex… [read post]